(E)-2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide | 1448295-54-2

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (E)-2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide
• 英文别名: N-[(E)-1-(4-methoxyphenyl)ethylideneamino]-2,4,6-tri(propan-2-yl)benzenesulfonamide
• CAS: 1448295-54-2
• 化学式: C₂₄H₃₄N₂O₃S
• 分子量: 430.612
• InChiKey: LBZZNTNGNVXBAU-XIEYBQDHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  30
• 可旋转键数：
  8
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  76.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  (E)-2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide 在 正丁基锂 、 氟双(苯基磺酰基)甲烷 作用下， 以 四氢呋喃 为溶剂， 反应 3.33h， 以54%的产率得到1-(1-氟乙烯基)-4-甲氧基苯
  参考文献：
  名称：

  Preparation of Fluoroalkenes via the Shapiro Reaction: Direct Access to Fluorinated Peptidomimetics

  摘要：

  Fluoroalkenes represent a useful class of peptidomimetics with distinct biophysical properties. Current preparations of this functional group commonly provide mixtures of E- or Z-fluoroalkene diastereomers, and/or mixtures of nonfluorinated products. To directly access fluoroalkenes in good stereoselectivity, a Shapiro fluorination reaction was developed. Fluoroalkene products were accessed in one- or two-step sequences from widely available ketones. This strategy should be useful for the preparation of fluorinated analogs of peptide-based therapeutics, many of which would be challenging to prepare by alternate strategies.

  DOI：

  10.1021/ol401637n
• 作为产物：
  描述：

  2,4,6-三异丙基苯磺酰氯 在 盐酸 、 肼 作用下， 以 四氢呋喃 为溶剂， 反应 8.0h， 生成 (E)-2,4,6-triisopropyl-N'-(1-(4-methoxyphenyl)ethylidene)benzenesulfonohydrazide
  参考文献：
  名称：

  Preparation of Fluoroalkenes via the Shapiro Reaction: Direct Access to Fluorinated Peptidomimetics

  摘要：

  Fluoroalkenes represent a useful class of peptidomimetics with distinct biophysical properties. Current preparations of this functional group commonly provide mixtures of E- or Z-fluoroalkene diastereomers, and/or mixtures of nonfluorinated products. To directly access fluoroalkenes in good stereoselectivity, a Shapiro fluorination reaction was developed. Fluoroalkene products were accessed in one- or two-step sequences from widely available ketones. This strategy should be useful for the preparation of fluorinated analogs of peptide-based therapeutics, many of which would be challenging to prepare by alternate strategies.

  DOI：

  10.1021/ol401637n

文献信息

• [EN] 1-(2-AMINO-1-PHENYL-ETHYL) 1- SILACYCLOHEXAN-1- OL DERIVATIVES AND USE THEREOF IN THE PREPARATION OF A MEDICAMENT<br/>[FR] DERIVES DE 1-(2-AMINO-1-PHENYL-ETHYL)-SILACYCLOHEXAN-1-OL ET UTILISATION DESDITS DERIVES POUR PREPARER UN MEDICAMENT
  申请人：AMEDIS PHARM LTD

  公开号：WO2004094436A1

  公开（公告）日：2004-11-04

  A compound selected from: (RS)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol (S)-1-[2-amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-dimethylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-amino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)- 1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (R)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (S)-1-[2-methylamino-1-(4-hydroxyphenyl)ethyl]-1-silacyclohexan-1-ol; (RS)-1-[2-dimethyl amino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; (R)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-l,4-diol; and (S)-1-[2-dimethylamino-1-(4-methoxyphenyl)ethyl]-1-silacyclohexan-1,4-diol; or a pharmaceutically acceptable salt thereof or a prodrug form that is hydrolysable to a compound as defined above.

  从中选择的化合物：(RS)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-二甲基氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(R)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(S)-1-[2-甲氨基-1-(4-羟基苯基)乙基]-1-硅环己烷-1-醇；(RS)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；(R)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；以及(S)-1-[2-二甲基氨基-1-(4-甲氧基苯基)乙基]-1-硅环己烷-1,4-二醇；或其药学上可接受的盐或可水解为上述定义的化合物的前药形式。
• Silicon compounds
  申请人：Tacke Reinhold

  公开号：US20050020541A1

  公开（公告）日：2005-01-27

  A compound of formula (I): wherein R 1 and R 2 are, independently, hydrogen or alkyl or together, with the nitrogen atom, form a heterocyclyl; R 3 and R 4 are, independently, hydrogen, hydroxyl, alkyl, alkoxy, alkanoyloxy, cyano, nitro, alkylmercapto, amino, alkylamino, dialkylamino, alkanamido, halogen or trifluoromethyl; R 5 is hydrogen or alkyl; and n is 0, 1, 2, 3 or 4; or a pharmaceutically acceptable salt thereof or a prodrug form that is hydrolysable to a compound as defined above.

  公式（I）的化合物：其中R1和R2独立地为氢或烷基，或者与氮原子一起形成杂环基；R3和R4独立地为氢、羟基、烷基、烷氧基、烷酰氧基、氰基、硝基、烷硫基、氨基、烷基氨基、二烷基氨基、烷酰胺基、卤素或三氟甲基；R5为氢或烷基；n为0、1、2、3或4；或其药学上可接受的盐或可以水解为上述化合物的前药形式。
• US4686309A
  申请人：——

  公开号：US4686309A

  公开（公告）日：1987-08-11
• US4755599A
  申请人：——

  公开号：US4755599A

  公开（公告）日：1988-07-05